Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Updates from the CHECKMATE-275 trial

Arlene Siefker-Radtke • 3 Jun 2019
ASCO 2019
Genitourinary Cancer Nivolumab
CheckMate 275

Arlene Siefker-Radtke, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses updates to the NCT02387996 This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Arlene Siefker-Radtke

1:47
The future role of erdafitinib in advanced urothelial carcinoma
Arlene Siefker-Radtke • 4 Jun 2023
1:34
RAGNAR: histology-agnostic trial of erdafitinib in FGFR3-mutant tumors
Arlene Siefker-Radtke • 4 Jun 2023
2:34
NORSE: erdafitinib and cetrelimab in urothelial carcinoma
Arlene Siefker-Radtke • 4 Jun 2023
1:15
What role will erdafitinib play in treating metastatic urothelial carcinoma?
Arlene Siefker-Radtke • 4 Jun 2023

Related Videos

3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals